T
Tami Rashal, M.D.,
MD/MBA Chief Medical Officer
Tami is the Chief Medical Officer of SBH Sciences and SBH Bioventure, bringing over a decade of experience in clinical research, drug development, and hospital practice. A distinguished board-certified hematologist-oncologist and accomplished entrepreneur, Dr. Rashal has successfully led three New Drug Applications (NDAs) and multiple Investigational New Drug (IND) submissions, demonstrating her expertise in advancing novel therapies to patients.
At SBH Sciences, Dr. Rashal plays a pivotal leadership role in expanding the company’s service offerings. Her focuses includes comprehensive IND submission support, medical and regulatory strategy development, protocol design and clinical trial execution, and enhanced medical affairs including engagement with Key Opinion Leaders (KOLs) and development of PDX models. In addition to expanding SBH’s service offerings, Dr. Rashal will focus on supporting biotech startups, leading due diligence, and fostering opportunities for non-dilutive funding to ensure long-term success and sustainability. Her strategic insights and collaborative approach will play a key role in SBH Sciences’ continued growth and success.
Before joining SBH Sciences. Dr. Rashal was the CEO of Merlin Health, an AI-based clinical trial decision-making tool, where she demonstrated her ability to drive complex projects and lead high-performing cross-functional teams to success.
Dr. Rashal completed her internal medicine training at Sheba Medical Center (Tel Hashomer) and her hematology-oncology fellowship at Sourasky Medical Center (Ichilov). She earned her M.D. from Semmelweis University and an MBA in Health Care Administration from Tel Aviv University.